Malta - English - Medicines Authority

leo pharma a/s industriparken 55, 2750-dk ballerup, denmark - calcipotriol - cream - calcipotriol 50 µg/g - antipsoriatics

Malta - English - Medicines Authority

leo pharma a/s - fusidate sodium - ointment - fusidate sodium 20 mg/g - antibiotics and chemotherapeutics for dermatological use

Australia - English - Department of Health (Therapeutic Goods Administration)

vertex pharmaceuticals australia pty ltd - ivacaftor, quantity: 75 mg - granules - excipient ingredients: hypromellose acetate succinate; sodium lauryl sulfate; lactose monohydrate; mannitol; sucralose; croscarmellose sodium; silicon dioxide; magnesium stearate - kalydeco is indicated for the treatment of cystic fibrosis (cf) in patients aged 4 months and older who have at least one mutation in the cftr gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data(see section 4.4 special warnings and precautions for use, and section 5.1 pharmacodynamic properties).

Australia - English - Department of Health (Therapeutic Goods Administration)

vertex pharmaceuticals australia pty ltd - ivacaftor, quantity: 50 mg - granules - excipient ingredients: hypromellose acetate succinate; sodium lauryl sulfate; lactose monohydrate; mannitol; sucralose; croscarmellose sodium; silicon dioxide; magnesium stearate - kalydeco is indicated for the treatment of cystic fibrosis (cf) in patients aged 4 months and older who have at least one mutation in the cftr gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data(see section 4.4 special warnings and precautions for use, and section 5.1 pharmacodynamic properties).

Australia - English - Department of Health (Therapeutic Goods Administration)

vertex pharmaceuticals australia pty ltd - ivacaftor, quantity: 125 mg; lumacaftor, quantity: 200 mg - tablet, film coated - excipient ingredients: hypromellose acetate succinate; sodium lauryl sulfate; microcrystalline cellulose; povidone; magnesium stearate; croscarmellose sodium; titanium dioxide; purified water; purified talc; brilliant blue fcf aluminium lake; polyvinyl alcohol; macrogol 3350; cochineal; indigo carmine aluminium lake; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Australia - English - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - mercaptopurine monohydrate, quantity: 20 mg/ml - oral liquid, suspension - excipient ingredients: xanthan gum; aspartame; rubus idaeus; sodium methyl hydroxybenzoate; sodium ethyl hydroxybenzoate; potassium sorbate; sodium hydroxide; purified water - allmercap oral liquid suspension is indicated for: treatment of acute lymphoblastic leukaemia (all) in paediatric patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - brentuximab vedotin, quantity: 50 mg - injection, powder for - excipient ingredients: citric acid monohydrate; trehalose dihydrate; sodium citrate dihydrate; polysorbate 80 - hodgkin lymphoma,treatment of patients with previously untreated cd30+ stage iii or stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine, and dacarbazine (avd).,treatment of adult patients with cd30+ hl at higher risk of relapse or progression following asct.,treatment of adult patients with relapsed or refractory cd30+ hl:,1. following autologous stem cell transplant (asct) or,2. following at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option.,peripheral t-cell lymphoma,treatment of adult patients with previously untreated cd30+ peripheral t-cell lymphoma (ptcl) in combination with cyclophosphamide, doxorubicin, and prednisone (chp).,treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (salcl).,cutaneous t cell lymphoma,treatment of adult patients with cd30+ cutaneous t-cell lymphoma (ctcl) after at least 1 prior systemic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

vertex pharmaceuticals australia pty ltd - ivacaftor, quantity: 150 mg - tablet, film coated - excipient ingredients: carnauba wax; croscarmellose sodium; silicon dioxide; magnesium stearate; microcrystalline cellulose; sodium lauryl sulfate; hypromellose acetate succinate; lactose monohydrate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - kalydeco is indicated for the treatment of cystic fibrosis (cf) in patients aged 4 months and older who have at least one mutation in the cftr gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data(see section 4.4 special warnings and precautions for use, and section 5.1 pharmacodynamic properties)

Australia - English - Department of Health (Therapeutic Goods Administration)

vertex pharmaceuticals australia pty ltd - ivacaftor, quantity: 150 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; croscarmellose sodium; silicon dioxide; carnauba wax; sodium lauryl sulfate; hypromellose acetate succinate; lactose monohydrate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - kalydeco is indicated for the treatment of cystic fibrosis (cf) in patients aged 4 months and older who have at least one mutation in the cftr gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data(see section 4.4 special warnings and precautions for use, and section 5.1 pharmacodynamic properties)

United States - English - NLM (National Library of Medicine)

macleods pharmaceuticals limited - levofloxacin (unii: 6gnt3y5lmf) (levofloxacin anhydrous - unii:rix4e89y14) - levofloxacin anhydrous 250 mg - levofloxacin tablets are indicated in adult patients for the treatment of nosocomial pneumonia due to methicillin-susceptible staphylococcus aureus, pseudomonas aeruginosa, serratia marcescens, escherichia coli, klebsiella pneumoniae, haemophilus influenzae, or streptococcus pneumoniae. adjunctive therapy should be used as clinically indicated. where pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see clinical studies (14.1) ]. levofloxacin tablets are indicated in adult patients for the treatment of community-acquired pneumonia due to methicillin-susceptible staphylococcus aureus , streptococcus pneumoniae (including multi-drug-resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, haemophilus parainfluenzae, klebsiella pneumoniae, moraxella catarrhalis, chlamydophila pneumoniae, legionella pneumophila , or mycoplasma pneumoniae [see dosage and administration ( 2.1 ) and clinical studies (14.2 )]. mdrsp i